INTRODUCTION

Generic drugs have become an essential part of modern healthcare systems,

providing patients with more affordable and accessible treatment options. Generic
drugs are copies of branded drugs that have already been approved by regulatory
authorities and have shown to be safe and effective in treating certain conditions.
They offer the same quality, safety, and efficacy as the original drug, but at a lower
cost, making them accessible to a larger patient population. Generic drugs have
played a crucial role in reducing healthcare costs, increasing patient access to
treatment, and improving the overall efficiency of healthcare systems.
According to the definition given by the World Health Organization (WHO), generic
medicines or generics are pharmaceutical products usually intended to be
interchangeable with the innovator product, marketed when period of patent is over
or other exclusivity rights. Generic or branded medicines are not clearly defined
under the Drugs & Cosmetics Act, 1940 and Rules, 1945. However, generic
medicines are those which contain same active ingredient with same amount in
same dosage form, administered by the same route of administration and equivalent
safety and efficacy as that of branded medicines. After all; brand-name companies
have made distinctive colors, shapes, and sizes part of their sales strategy.
Generic drugs usually cheaper than the innovator drug because of the following
reasons: -

● No cost of identification and isolation of New Chemical Entity (NCE),

● No cost of research and development,

● Minimum marketing cost because Branded drug is already approved as safe

and effective.
A generic drug can be produced for the Drugs: -

● Where the patent has expired

● Which have never held patent

● In countries where a patent(s) is/are not in force

Basic Requirement of Generic Medicines

There are some mandatory rules to develop a generic product and the following
parameters should be same as the innovator for developing any generic:

● The Active Pharmaceutical Ingredient and use.

 ● Dose and strength

● The route of administration (1)

ADVANTAGES

⮚ Generics are cost effective. They can reduce the cost of innovator product up
to 80%
⮚ Generic drugs can make sure that medicines and treatment are available to
all financial class of people in the respective country.
⮚ Generics make sure that there are no shortage of medicine supply in the
concerned country
⮚ The concept of generic industry makes it possible even for a small
pharmaceutical company to have some market share and profit compared to
the bigger pharmaceutical players
⮚ Promotes research in pharmaceutical area

⮚ Establishment of generic industry has decreased the clandestine arrangement

between doctors and innovator companies because of the increased
competition for market share
⮚ Eliminate the monopoly of big innovator companies

GENERIC DRUG APPROVAL PROCESS

Each year, FDA’s Center for Drug Evaluation and Research (CDER) approves a
wide range of new drug products. FDA provides the scientific and regulatory advice
needed to bring safe, effective, high-quality generic alternatives to market, which in
turn creates more affordable treatment options for patients. Like any other scientific
and regulatory process, approval of a generic drug takes time. It takes FDA time to
review the complex information needed to demonstrate that a given generic drug can
be substituted for the brand-name drug that it copies, and that time also depends on
the complexity of the drug product and the completeness of the application.
The generic drug approval process has evolved over the past 35 years. In 1970 FDA
established the Abbreviated New Drug Application (ANDA) as a mechanism for the
review and approval of generic versions of drug products that had been approved
between 1938 and 1962.
Before 1978, generic product applicants were required to submit complete safety
and efficacy through clinical trials. Post 1978, applicants were required to submit
published reports of such trials documenting safety and efficacy. Neither of these
approaches was considered satisfactory and so originated hatch Waxman act on
1984.(2)
An abbreviated new drug application (ANDA) is an application submitted to FDA of
United states for the review and approval of a generic drug product.
Once approved, an applicant may manufacture and market the generic drug product
in US. A generic drug product are identical and similar to innovator or branded drugs
with respect purity, strength, performance characteristics, intended use, stability, and
quality. It act as a safe, effective and low cost alternative to the brand-name drug.
The term “abbreviated” is used because they are generally not required to include
preclinical (animal) and clinical (human) data to establish safety and effectiveness.
Instead ANDA applicant should demonstrate the bioequivalence of the drug with that
of the innovator drug.
RESEARCH RATIONALE:
This research is driven by the following rationale:
Growing Dependence on Generic Drugs for Affordable Healthcare Access –
Rising healthcare costs and the high prices of brand-name medicines have
increased global reliance on generic drugs as a more affordable alternative.
However, there is still limited academic research exploring how these drugs are
regulated and approved, especially within the U.S. system that shapes much of the
global pharmaceutical market.
Knowledge Gaps in Understanding the FDA’s Approval Process for Generics –
Although generic drugs play a major role in improving patient access, the detailed
steps, challenges, and timeframes involved in their approval through the FDA’s
Abbreviated New Drug Application (ANDA) process are not widely understood.
These gaps make it difficult for researchers, policymakers, and manufacturers to
identify ways to make the system more efficient and transparent.
Market Size and Global Influence
The United States is the world’s largest pharmaceutical market, with generics
accounting for approximately 90% of prescriptions dispensed. The policies, approval
efficiency, and quality assurance mechanisms in this market significantly affect
global trends and pricing.
Personal and Academic Motivation to Study U.S. FDA Regulations –
The researcher’s academic background and strong interest in U.S. FDA drug
regulations provide a meaningful foundation for analyzing and evaluating the
processes that determine how quickly and safely generic drugs reach the market.
The global generic pharmaceuticals market has experienced substantial growth
due to increasing healthcare costs, patent expirations of major branded drugs, and
government initiatives promoting cost-effective medicines.
The global market for Generic Drugs estimated at US$403.9 Billion in the year 2022,
is projected to reach a revised size of US$671.5 Billion by 2030, growing at a CAGR
of 6.6% over the analysis period 2022-2030. The growth of the generic
pharmaceuticals market is largely attributable to the expiry of product patents which
clears the way for generic drugs manufacturers to launch products in the market.
In the United States, 9 out of 10 prescriptions filled are for generic drugs. Increasing
the availability of generic drugs helps to create competition in the marketplace, which
then helps to make treatment more affordable and increases access to healthcare
for more patients.
In the United States (US), the Food and Drug Administration (FDA) is responsible for
regulating the drug testing process in order to elicit potential health risks to
consumers. While both brand-name and generic drug companies in the US must
apply for FDA approval before being allowed to sell their drugs to the public, the
former is required to undergo pre-clinical and costly three phase clinical testing in
order to portray drug safety and efficacy. However, the latter is only required to
undergo bioequivalence testing, or testing of pharmacokinetic properties, accounting
for a significant discrepancy in expenditures between brand-name and generic drugs
and a subsequent inflation in the pricing of brand-name equivalents.
Discrepancies also exist in the drug policies of different countries, and this is the
cause for the varying extent of generic and brand-name drug sales in different parts
of the world. For example, the US has higher sales of generic drugs as compared to
Canada and the UK owing to its privatized health care system. In contrast,
governments in countries such as Canada and the UK cover a significant portion of
pharmaceutical related costs, thereby reducing consumer incentive to purchase
generic drugs at a lower price. However, in these countries, price restrictive policy
making and co-payment practices continue to play a large role in the market forces
that determine sales of generic drugs.
The purpose of this review is to conduct a comprehensive analysis of the regulatory
approval and registration process for generic drugs in the United States. Specifically,
it aims to investigate the procedures, requirements, and timelines involved in
obtaining approval through the Abbreviated New Drug Application (ANDA) pathway,
as well as the challenges and inefficiencies faced by pharmaceutical companies.
This review also seeks to incorporate insights from regulatory and R&D
professionals through an online survey, providing a practical perspective on the
approval process. Ultimately, the study is intended to identify areas for improvement
and propose recommendations that can enhance the efficiency, quality, and
predictability of generic drug approvals in the U.S., supporting timely access to
affordable medicines for patients and informed decision-making for stakeholders.
NEED FOR THE STUDY
Generic drugs form the backbone of affordable healthcare in the United States,
accounting for the majority of prescriptions dispensed. However,the regulatory
approval and registration process particularly through the Abbreviated New Drug
Application (ANDA) pathway in the USA remains complex, time-consuming, and
often hindered by procedural deficiencies, documentation gaps, and inconsistent
review timelines.

The regulatory barriers, frequent deficiencies in submissions, and market challenges

limit timely access to safe and effective generic medicines. Despite the FDA’s
continuous efforts to improve the process, there is still a need to better understand
these obstacles and propose ways to streamline the system.

Therefore,there is a strong need to study this area to understand the reasons for
these challenges and to identify ways to make the approval process faster and more
efficient without affecting quality or safety. By analyzing both the regulatory
framework and the real experiences of professionals, this study can help suggest
practical improvements that will support quicker access to safe and affordable
generic medicines for the public.

KNOWLEDGE GAP
This study aim to address a significant gap in understanding the regulatory
approval and registration process for generic drug in usa. Understanding the
regulatory efficiency, bioequivalence assessment, and real-world performance of
generic drugs in the United States remains a critical knowledge gap for stakeholders,
including manufacturers, healthcare providers, and patients. Despite the well-
established FDA framework for generic approvals, limited research exists on how
regulatory processes, patent barriers, and market dynamics influence the timely
availability, quality, and affordability of generic medicines. Addressing this gap is
essential to enhance regulatory transparency, promote innovation, and improve
patient access to safe and cost-effective therapies.

RESEARCH PROBLEMS
Approving generic drugs in the United States is challenging because companies
must show that their products are as safe and effective as the original drugs, which
can be tough for complex medicines. Meeting strict FDA rules, preparing perfect
paperwork, and keeping up with changing standards like new rules about impurities
often causes delays and rejections. Beyond scientific and procedural hurdles, the
generic approval pathway is affected by legal, economic, and market barriers. Patent
litigations and exclusivity disputes with original brand manufacturers can significantly
delay market entry even after obtaining FDA approval.
Smaller companies new to the regulatory system often face significant resource
limitations and lack the necessary experience to prepare successful ANDA
submissions. Understanding why only a small percentage of generic applications are
approved in the first review cycle requires addressing these multiple challenges.
Research aimed at these issues is essential to develop strategies that can simplify
the approval process, reduce delays, and ultimately ensure that affordable medicines
become accessible to patients without unnecessary hurdles.

RESEARCH QUESTIONS
To examine the identified problems,Research questions are aligned with the study
of aim and objectives to examine the ANDA approval process and its regulatory
challenges in the United States.
[Link] challenges and barriers are experienced by regulatory and R&D
professionals during the ANDA submission and approval process in the United
States?

[Link] are the regulatory frameworks, pathways, timelines and documentation

requirements governing the approval of generic drugs through the ANDA pathway in
the United States?

[Link] do regulatory and R&D professionals recognise the efficiency, communication

transparency, and review consistency of the U.S. FDA in the generic drug approval
system?
[Link] strategic regulatory and process enhancements can be recommended to
improve the efficiency, quality, and timeliness of generic drug approvals in the United
States?

REVIEW OF LITERATURE
Pandhare ShubhamD and Wamane Vikas B (2023) in the article entitled “Generic
Drug Development and Current Scenario” provide an extensive analysis of the
scientific, regulatory, and manufacturing factors governing the development of
generic medicines. This highlights the entry of generic medicines in market brought a
revolutionary change in healthcare system and the market share is continuously
increasing. In the present scenario generic drugs have an important role in
pharmaceutical [Link] review presents considerations which can be employed
during the development of a semisolid topical generic product. This includes a
discussion on the implementation of quality by design concepts during development
to ensure the generic drug product has similar desired quality attributes to the
reference-listed drug (RLD) and ensure batch to batch consistency through
commercial production. Their article emphasizes the importance of pre-formulation
studies, including solubility profiling, polymorphism, drug–excipient compatibility, and
physicochemical characterization, as the foundation for designing a robust generic
formulation. They also highlight the role of quality-by-design approaches in ensuring
that critical quality attributes—such as dissolution behavior and stability—match
those of the reference listed drug. The review underscores the scientific rigor
required in selecting excipients, optimizing manufacturing methods such as
granulation or direct compression, and validating scale-up processes to achieve
batch-to-batch uniformity, reflecting the increasing complexity of generic drug
development.
Singh et al. (2023), in their article “Impact of Regulatory Policy Changes on Generic
Drug Prices in the United States,” examine how U.S. regulatory reforms, starting with
the 1984 Hatch-Waxman Act—which established the Abbreviated New Drug
Application (ANDA) pathway to streamline generic approvals by demonstrating
bioequivalence rather than repeating full clinical trials, thereby increasing generic
entry probability from 40% to 91.5% and market share from under 20% to over 90%
of prescriptions—combined with subsequent Generic Drug User Fee Act (GDUFA)
programs (2012 onward), have accelerated approvals, enhanced competition, and
substantially reduced prices (e.g., median declines exceeding 30% after the first
generic entrant, 44% after the second, and nearly 98% with 10+ competitors,
according to FDA analyses). The authors highlight that generics now represent just
18% of total U.S. drug spending while generating over $2.4 trillion in savings from
2011–2020, supported by offshoring to low-cost producers like India (supplying
~40% of U.S. generics), and note complementary measures such as the CREATES
Act (2019) for reference product sample access and CARES Act provisions to
mitigate shortages that drive price spikes. Despite these advances amid rising per-
capita drug costs and Medicare sustainability challenges, the review identifies
ongoing brand-name tactics—like pay-for-delay settlements, citizen petitions,
product hopping, and REMS-related delays—that hinder competition and elevate
payer expenses (e.g., $761 million excess Medicaid costs from 2010–2016),
recommending stronger Federal Trade Commission (FTC) enforcement on mergers
and further FDA guidance for complex generics.
Patil et al. (2024), in their article “Current Regulatory Framework and Challenges for
the Approval of Complex Generics in the US and the EU,” reviewed the approval
process for complex generic drugs in the United States and the European Union.
The authors explain that in the US, complex generics are mainly approved through
the Abbreviated New Drug Application (ANDA) pathway, using FDA product-specific
guidance, while in the EU they are approved through generic or hybrid applications
when standard bioequivalence studies are not sufficient. The review highlights major
challenges such as difficulty in properly analyzing complex formulations, limitations
of usual bioequivalence methods for locally acting products, complex manufacturing
processes, and differences in regulatory requirements between the US and EU.
These challenges often lead to delays in approval, increased development costs,
and uncertainty for manufacturers. The authors conclude that clearer regulatory
guidelines, better analytical methods, and greater regulatory harmonization between
the US and Europe are needed to support faster approval and wider availability of
complex generic medicines.

Naseela et al.(2024)in their article “Comparative overview of genetic drug

regulation in USA ,UK,and India” reviewed the regulatory approval process
in USA, UK and India. They stated that the consumers in the US are saving
a lot of money thanks to the sharp rise in the use of generic
Pharmaceuticals. In order to help the Department of Health and Human
Services (HHS) Discover strategies to encourage the use of generic drugs,
Secretary Sebelius asked the Assistant Secretary for Planning and
Evaluation (ASPE) to look into possible opportunities and roadblocks to
doing [Link] Food and Drug Administration (FDA) requires innovative new
drugs to file a new drug Application that includes data from clinical trials
that demonstrate the drug’s safety and Efficacy in order to approve their
branded pharmaceuticals. Innovative branded Pharmaceutical companies
spend a lot of money and effort on drug development and Regulatory
approval. According to some estimates, the time and financial resources
required to bring a Breakthrough drug to market can easily surpass one
billion dollars. Generic versions of drugs Are equally effective as name-
brand ones. Every aspect of a medication, including the active Ingredient,
strength, dosage form, and mode of administration, must be chemically and
Medicinally similar in generic form to the original, branded version. The
inactive ingredients In generic equivalents of name-brand drugs don’t have
to be the same.
The Hatch-Waxman Act has been successful in accomplishing its two
objectives, which were to reduce the cost of pharmaceuticals for
consumers and to encourage innovative pharmaceutical companies to
continue the development of revolutionary drugs. By offering financial
incentives to well-known companies, Hatch-Waxman developed a
legislative framework with the intention of preventing the introduction of
generic drugs.
As the patents on branded drugs are set to expire, the generic medicine
production sector of The pharmaceutical business is experiencing
tremendous growth. One of the most important International strategies that
aims to cut the costs of medical care and increase the number of Patients
who have access to prescription medications is to encourage the
manufacture of Generic pharmaceutical companies. Those that produce
generic drugs have the option of Submitting a reduced version of the New
Drug Application (ANDA), which only includes Bioequivalency studies. It
includes the information regarding the effectiveness and safety of The drug
that was provided by the initial innovative medication manufacturer.

AIM AND OBJECTIVE

AIM :

● The aim of the study is to conduct a comprehensive analysis of the

regulatory approval processes for generic drugs in the United States, with

the goal of understanding the regulatory frameworks, pathways,

requirements, timelines, and challenges involved, and to propose

improvements that can enhance the efficiency and quality of generic drug

approval process.

OBJECTIVE:
 • To analyze the procedure involved in the approval of generic drugs through

the Abbreviated New Drug Application (ANDA) pathway in the USA.

• To conduct an online survey targeting regulatory and R&D professionals in

pharmaceutical companies to uncover valuable insights on their

experiences, challenges, and perceptions of the approval and registration

processes for generic drugs in U.S.

• To propose recommendations for improving the approval and registration

process for generic drugs in United States.

REFERENCES
1. Rahman P, Mehnaz S. International Journal for Multidisciplinary Research
(IJFMR). SSRN Electron J [Internet]. 2024 [cited 2025 Nov 13]; Available from:
[Link]
2. Dharani T, Kumar PP, Phanindra DS, Nagabhushanam MV, Bonthagarala B,
Ramakrishna G, et al. A REVIEW ON ABBREVIATED NEW DRUG
APPLICATION (ANDA). World J Pharm Pharm Sci.